Hyphens Pharma Bags Rights To Stelara Rival

DKSH’s Favorex Licenses Alvotech’s Ustekinumab In Singapore, Malaysia And Philippines

 
• By Dave Wallace

Hyphens Pharma has struck a licensing deal with DKSH’s Favorex to secure rights to Alvotech’s proposed ustekinumab rival to Stelara in Singapore, Malaysia and the Philippines.

South-east Asia From Space Globe Planet Earth
Hyphens Pharma has secured rights to ustekinumab in south-east Asia • Source: Alamy

More from Deals

More from Business